



Cochlear[®]
Hear now. And always



Cochlear[™] Nucleus[®] System
Adult Cochlear[™]
Connected Care model
quick guide

Activation

Optimization

Maintenance

	Within 2 weeks post surgery (0–14 days)	1–3 months post surgery
Timing		
Programming	<ul style="list-style-type: none"> <input type="checkbox"/> Inspect implant site, select magnet strength <input type="checkbox"/> Activate using population mean <input type="checkbox"/> Minimum dynamic range: 40 CL Streamlined workflow default: 46 CL <input type="checkbox"/> Globally increase T and C levels together until “Loud.” This may take several minutes as the patient habituates to electric stimulation <input type="checkbox"/> Sweep Cs in bands to ensure broadly equivalent loudness across the array. Stimulation should be “loud” for each band across the frequency range <input type="checkbox"/> Program 1: SCAN 2 FF, Program 2: SCAN 2 <input type="checkbox"/> Activate Master Volume Bass & Treble (MVBT) 	<ul style="list-style-type: none"> <input type="checkbox"/> Inspect the implant site and equipment, assess magnet strength <input type="checkbox"/> C Levels: Ensure appropriate and equal loudness across bands of electrodes <input type="checkbox"/> T Levels: Measure streamlined Ts (at least 5) at least once in the Optimization phase, ensuring they are set at the lowest level that is 100% audible <ul style="list-style-type: none"> • Reassess only when there are sound quality or audibility concerns <input type="checkbox"/> Cross check the MAP using objective measures <ul style="list-style-type: none"> • eSRT thresholds are typically ~15 CL above C levels^{1,2} • tNRT thresholds typically fall between T and C levels of a MAP with the same pulse width³
Audibility, speech perception, patient satisfaction	<ul style="list-style-type: none"> <input type="checkbox"/> Ensure audibility using Ling sounds or other informal measure 	<ul style="list-style-type: none"> <input type="checkbox"/> Remote Check: Aided Threshold Test (ATT) for audibility and Digit Triplet Test (DTT) for speech in noise. <input type="checkbox"/> Sound Booth: Measure soundfield audibility, CNCs in the implanted ear, and AzBio +10 in the everyday listening condition <input type="checkbox"/> Administer patient reported outcome measure (e.g. CIQOL, SSQ)
Contralateral ear	<ul style="list-style-type: none"> <input type="checkbox"/> Bimodal: Link smart bimodal device <input type="checkbox"/> Bilateral CI: Balance loudness between two ears 	<ul style="list-style-type: none"> <input type="checkbox"/> Consider bilateral cochlear implantation for appropriate candidates <input type="checkbox"/> Bimodal: Fit and link smart bimodal device as needed <input type="checkbox"/> Bilateral CI: Balance loudness between two ears
Patient empowerment	<ul style="list-style-type: none"> <input type="checkbox"/> Recommend 10+ hours of daily use <input type="checkbox"/> Instruct on use of MVBT to self-manage loudness and sound quality <input type="checkbox"/> Ensure registration of all patient equipment <input type="checkbox"/> Schedule virtual patient appointment with the Recipient Solutions Manager (RSM) for introductory device education and aural rehabilitation guidance <input type="checkbox"/> Review Aural Rehab materials (e.g. manual, Cochlear CoPilot) 	<ul style="list-style-type: none"> <input type="checkbox"/> Confirm 10+ hours of daily use <input type="checkbox"/> Review progress results with the patient <input type="checkbox"/> Enroll in Remote Care. Once the patient has met their milestones (see right column), assign a baseline in Remote Check <input type="checkbox"/> Ensure patient is continuing to access RSM services for accessory support, rehabilitation guidance, and other patient education <input type="checkbox"/> Encourage use of MVBT to manage sound quality

Timing	Graduate those meeting milestones to annual monitoring at approximately the 90-day appointment (3+ months post surgery)
Milestones	<ul style="list-style-type: none"> <input type="checkbox"/> At ~3 months, CNC scores in the implanted ear of ≥56% or ≥20% improvement from preoperative baseline <ul style="list-style-type: none"> • This ensures the patient is achieving above average performance or a clinically significant improvement in speech perception^{4,5} <input type="checkbox"/> Appropriate audibility of better than 30 dB HL with the cochlear implant only <ul style="list-style-type: none"> • Appropriate access to soft sounds is associated with improved performance⁶ <input type="checkbox"/> Appropriate device use of 10+ hours per day <ul style="list-style-type: none"> • Full time cochlear implant use is associated with improved performance⁷ <input type="checkbox"/> Patient reported satisfaction assessed formally (e.g. CIQOL, SSQ) or informally <ul style="list-style-type: none"> • This measures the patient’s hearing experience with their cochlear implant to ensure subjective benefit
Maintenance goals	<ul style="list-style-type: none"> <input type="checkbox"/> Use Remote Check to monitor the patient’s performance when possible <ul style="list-style-type: none"> • Note that a change of 3 dB or greater is considered a clinically significant change on the Digit Triplet Test⁸ <input type="checkbox"/> Reassess T and C levels when indicated by performance changes or to address patient reported concerns <input type="checkbox"/> Assess patient’s other ear for potential CI candidacy <input type="checkbox"/> Encourage patient to connect with Cochlear directly for support and troubleshooting <input type="checkbox"/> Consider an upgrade (e.g. after 5+ years after initial processor fitting)

Cochlear resources

Care Model website

www.cochlear.us/caremodel



Recipient Solutions Manager

cochlear.us/rsmbooking



Audiologist on Call (AOC)

877 883 3101

Device support

877 651 7001

support.cochlear.com/us/en/home

Billing and coding support

800 587 6910

codingsupport@cochlear.com

Hear now. And always

Cochlear is dedicated to helping people with moderate to profound hearing loss experience a world full of hearing. As the global leader in implantable hearing solutions, we have provided more than 750,000 devices and helped people of all ages to hear and connect with life's opportunities.

We aim to give people the best lifelong hearing experience and access to next generation technologies. We collaborate with leading clinical, research and support networks to advance hearing science and improve care.

That's why more people choose Cochlear than any other hearing implant company.

References

1. Holder JT, Henry MR, MacDonald AE, Gifford RH. Cochlear Implant Upper Stimulation Levels: eSRT vs. Loudness Scaling. *Otol Neurotol.* 2023 Oct 1;44(9):e667-e672. doi: 10.1097/MAO.0000000000003988. Epub 2023 Aug 23. PMID: 37621113; PMCID: PMC10637929.
2. Holder, J.T. 2022. The Role of eSRT in Device Programming. Maximizing Performance in Cochlear Implant Recipients: Programming Concepts. New York, NY, United States.
3. Di Nardo W, Ippolito S, Quaranta N, Cadoni G, Galli J. Correlation between NRT measurement and behavioural levels in patients with the Nucleus 24 cochlear implant. *Acta Otorhinolaryngol Ital.* 2003 Oct;23(5):352-5. PMID: 15108484.
4. Cochlear Limited 2019. Nucleus CI532 data on file.
5. Buchman CA, Herzog JA, McJunkin JL, Wick CC, Durakovic N, Firszt JB, Kallogjeri D; CI532 Study Group. Assessment of Speech Understanding After Cochlear Implantation in Adult Hearing Aid Users: A Nonrandomized Controlled Trial. *JAMA Otolaryngol Head Neck Surg.* 2020 Oct 1;146(10):916-924. doi: 10.1001/jamaoto.2020.1584. PMID: 32857113; PMCID: PMC7453346.
6. de Graaff F, Lissenberg-Witte BI, Kaandorp MW, Merkus P, Goverts ST, Kramer SE, Smits C. Relationship Between Speech Recognition in Quiet and Noise and Fitting Parameters, Impedances and ECAP Thresholds in Adult Cochlear Implant Users. *Ear Hear.* 2020 Jul/Aug;41(4):935-947. doi: 10.1097/AUD.0000000000000814. PMID: 31702597.
7. Holder JT, Dwyer NC, Gifford RH. Duration of Processor Use Per Day Is Significantly Correlated With Speech Recognition Abilities in Adults With Cochlear Implants. *Otol Neurotol.* 2020 Feb;41(2):e227-e231. doi: 10.1097/MAO.0000000000002477. PMID: 31789794; PMCID: PMC6954337.
8. Maruthurkara S, Case S, Rottier R. Evaluation of Remote Check: A Clinical Tool for Asynchronous Monitoring and Triage of Cochlear Implant Recipients. *Ear Hear.* 2022 Mar/Apr;43(2):495-506. doi: 10.1097/AUD.0000000000001106. PMID: 34320523; PMCID: PMC8862779.

This is meant to be an at-a-glance resource. Excluded from this guidance are assessment of residual hearing, alternative MAP initiation methods, SSD recommendations, and EAS recommendations. Please see full Adult CI Protocol for complete care recommendations.

Remote Check and Remote Assist for Nucleus sound processors are intended for ages 6 and older. Remote Check and Remote Assist features are only visible and accessible if they are enabled by a clinician. Clinicians should consider the suitability of the feature before enabling Remote Check and Remote Assist. Only available at clinics that have enrolled in Remote Care.

SNR-NR, WNR and SCAN are approved for use with any recipient ages 6 years and older who is able to 1) complete objective speech perception testing in quiet and in noise in order to determine and document performance 2) report a preference for different program settings.

ForwardFocus can only be enabled by a hearing implant specialist. It should only be activated for users 12 years and older who are able to reliably provide feedback on sound quality and understand how to use the feature when moving to different or changing environments. It may be possible to have decreased speech understanding when using ForwardFocus in a quiet environment.

©Cochlear Limited 2024. All rights reserved. ACE, Advance OffStylet, AOS, Ardium, AutoNRT, Autosensitivity, Baha, Baha SoftWear, BCDrive, Beam, Bring Back the Beat, Button, Carina, Cochlear, 科利耳, コクレア, 코클리어, Cochlear SoftWear, Contour, コントウア, Contour Advance, Custom Sound, DermaLock, Freedom, Hear now. And always, Hugfit, Human Design, Hybrid, Invisible Hearing, Kanso, LowPro, MET, MP3000, myCochlear, mySmartSound, NRT, Nucleus, Osia, Outcome Focused Fitting, Off-Stylet, Piezo Power, Profile, Slimline, SmartSound, Softip, SoundArc, SoundBand, True Wireless, the elliptical logo, Vistafix, Whisper, WindShield and Xidium are either trademarks or registered trademarks of the Cochlear group of companies.

Cochlear Americas

10350 Park Meadows Drive, Lone Tree, CO 80124, USA
Tel: +1 303 790 9010 Support: Tel: +1 800 483 3123

Cochlear Canada Inc.

2500-120 Adelaide Street West, Toronto, ON M5H 1T1, Canada
Tel: +1 800 483 3123 Fax: +1 416 972 5083

www.cochlear.com

